PubMed · 463589
Weight changes with depot neuroleptic maintenance therapy.
Abstract
A prospective study of schizophrenic patients prescribed injectable depot neuroleptic drugs as maintenance therapy showed a clinically significant weight gain in 55% of patients. No significant difference was shown between flupenthixol decanoate and fluphenazine decanoate, nor was a clinically meaningful relationship shown with dose, or the use of anti-parkinsonian drugs. The weight gain continued for at least 2 years following a mental state relapse. It is suggested that the monitoring of weight and giving of appropriate advice on diet are two essential in maintenance therapy of chronic schizophrenia.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
D A Johnson, M Breen. 1979. Weight changes with depot neuroleptic maintenance therapy.. https://doi.org/10.1111/j.1600-0447.1979.tb00252.x
Cite the original work for its findings. Save a collection to share your selection of sources.